TPTerezia Pincikova

Terezia Pincikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Terezia Pincikova has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor/tezacaftor/ivacaftor therapy

    by Elli Mouchtaridi, Aleksandra Kowalik, Elisa J. M. Raineri, Marion Humbert, Josef Jägerstedt, Margaret Bojarlind, Kristina Nilsson, Malin Flodström-Tullberg, Terezia Pincikova, Johan K. Sandberg

    Background: Therapy with elexacaftor/tezacaftor/ivacaftor (ETI) works to improve the functionality of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein and has revolutionized CF treatment. However, the implications of ETI for airway barrier and systemic T cell immunobiology remain relatively little studied. Methods: Here, we investigated the immunological effects of ETI at systemic and local pulmonary levels, using paired peripheral blood and sputum sampling, in relation to key clinical parameters. Samples were taken longitudinally at baseline ( n = 27), and at three ( n = 24) and 12 months ( n = 19) of treatment and subjected to analysis by advanced flow cytometry, T cell assays, and plasma proteomics. Results: Before ETI treatment initiation, immune cell composition in the sputum closely reflected the plasma inflammatory proteome. T cell abundance in sputum correlated inversely with multiple plasma factors, including IL-17A, IL-8, HGF and TGFα, and with lower sweat chloride concentrations. Chronic microbial infection was associated with low abundance of CD4 T cells and mucosa-associated invariant T (MAIT) cells in sputum samples collected at baseline. During ETI treatment, T cells with lung resident characteristics including MAIT cells increased in sputum, accompanied by improved lung function and reduced systemic inflammation. In peripheral blood, the effector-memory CD8 and CD4 T cell pool expanded and the magnitude and quality of T cell responses to Influenza A virus recovered during ETI. Conclusions: These findings indicate that ETI treatment promotes immunological remodelling in both airways and circulation, correlating with favorable changes in clinically relevant parameters, and a shift towards healthy immune regulation in the lung and improved adaptive T cell responses in circulation.


  • Open Access

    Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor/tezacaftor/ivacaftor therapy

    by Elli Mouchtaridi, Aleksandra Kowalik, Elisa J. M. Raineri, Marion Humbert, Josef Jägerstedt, Margaret Bojarlind, Kristina Nilsson, Malin Flodström-Tullberg, Terezia Pincikova, Johan K. Sandberg

    Background Therapy with elexacaftor/tezacaftor/ivacaftor (ETI) works to improve the functionality of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein and has revolutionized CF treatment. However, the implications of ETI for airway barrier and systemic T cell immunobiology remain relatively little studied. Methods Here, we investigated the immunological effects of ETI at systemic and local pulmonary levels, using paired peripheral blood and sputum sampling, in relation to key clinical parameters. Samples were taken longitudinally at baseline, and at three and 12 months of treatment and subjected to analysis by advanced flow cytometry, T cell assays, and plasma proteomics. Results Before ETI treatment initiation, immune cell composition in the sputum closely reflected the plasma inflammatory proteome. T cell abundance in sputum correlated inversely with multiple plasma factors, including IL-17A, IL-8, HGF and TGFα, and positively with better lung function and lower sweat chloride concentrations. Chronic microbial infection was associated with low abundance of CD4 T cells and mucosa-associated invariant T (MAIT) cells in sputum samples collected at baseline. During ETI treatment, T cells with lung resident characteristics including MAIT cells increased in sputum, accompanied by improved lung function and reduced systemic inflammation. In peripheral blood, the effector-memory CD8 and CD4 T cell pool expanded and the magnitude and quality of T cell responses to Influenza A virus recovered during ETI. Conclusions These findings indicate that ETI treatment promotes immunological remodelling in both airways and circulation, correlating with favorable changes in clinically relevant parameters, and a shift towards healthy immune regulation in the lung and improved adaptive T cell responses in circulation.

  • Open Access

    Expression Levels of MUC5AC and MUC5B in Airway Goblet Cells Are Associated with Traits of COPD and Progression of Chronic Airflow Limitation

    by Terezia Pincikova, Heta Merikallio, Ioanna Kotortsi, Reza Karimi, Chuan-Xing Li, Elisa Lappi-Blanco, Sara K. Lindén, Médea Padra, Åsa M. Wheelock, Sven Nyrén, et al.

    Mucins 5AC (MUC5AC) and 5B (MUC5B) are the major mucins providing the organizing framework for the airway’s mucus gel. We retrieved bronchial mucosal biopsies and bronchial wash (BW) samples through bronchoscopy from patients with chronic obstructive pulmonary disease (n = 38), healthy never-smokers (n = 40), and smokers with normal lung function (n = 40). The expression of MUC5AC and MUC5B was assessed immunohistochemically. The mucin concentrations in BW were determined using the slot-blot technique. The immunohistochemical expression of MUC5AC and MUC5B was localized to goblet cells and submucosal glands. Smokers had higher MUC5AC and lower MUC5B goblet cell expression and higher concentrations of soluble MUC5AC in BW than never-smokers. The MUC5B expression in goblet cells correlated positively with expiratory air flows, diffusing capacity, and the dyspnoea score. Chronic bronchitis, emphysema, and the progression of chronic airflow limitation during a median follow-up time of 8.4 years were associated with higher MUC5AC and lower MUC5B expression in goblet cells. Sustainers, slow progressors, and rapid progressors of airflow obstruction differed in their MUC5B expression at baseline. Emphysema and bronchial wall thickening on CT at a follow-up visit were associated with lower MUC5B expression at baseline. Our findings strengthen the hypothesis that MUC5AC and MUC5B are yet another contributing factor to smoking-associated lung disease progression.


  • Open Access

    Mucins 3A and 3B Are Expressed in the Epithelium of Human Large Airway

    by Heta Merikallio, Terezia Pincikova, Ioanna Kotortsi, Reza Karimi, Chuan-Xing Li, Helena Forsslund, Mikael Mikko, Sven Nyrén, Elisa Lappi-Blanco, Åsa M. Wheelock, et al.

    Aberrant mucus secretion is a hallmark of chronic obstructive pulmonary disease (COPD). Expression of the membrane-tethered mucins 3A and 3B (MUC3A, MUC3B) in human lung is largely unknown. In this observational cross-sectional study, we recruited subjects 45–65 years old from the general population of Stockholm, Sweden, during the years 2007–2011. Bronchial mucosal biopsies, bronchial brushings, and bronchoalveolar lavage fluid (BALF) were retrieved from COPD patients (n = 38), healthy never-smokers (n = 40), and smokers with normal lung function (n = 40). Protein expression of MUC3A and MUC3B in bronchial mucosal biopsies was assessed by immunohistochemical staining. In a subgroup of subjects (n = 28), MUC3A and MUC3B mRNAs were quantified in bronchial brushings using microarray. Non-parametric tests were used to perform correlation and group comparison analyses. A value of p < 0.05 was considered statistically significant. MUC3A and MUC3B immunohistochemical expression was localized to ciliated cells. MUC3B was also expressed in basal cells. MUC3A and MUC3B immunohistochemical expression was equal in all study groups but subjects with emphysema had higher MUC3A expression, compared to those without emphysema. Smokers had higher mRNA levels of MUC3A and MUC3B than non-smokers. MUC3A and MUC3B mRNA were higher in male subjects and correlated negatively with expiratory air flows. MUC3B mRNA correlated positively with total cell concentration and macrophage percentage, and negatively with CD4/CD8 T cell ratio in BALF. We concluded that MUC3A and MUC3B in large airways may be a marker of disease or may play a role in the pathophysiology of airway obstruction.


  • The Swedish Broncho-Scapis Cohort: Characterization of Chronic Airflow Limitation in Adult Never-Smokers

    by T. Pincikova, A. Andersson, L.H. Bjermer, A.C. Blomberg, J. Erjefält, C. Janson, H.L. Persson, E. Tufvesson, Wheelock, C.M. Sköld

  • Open Access

    MAIT cell counts are associated with the risk of hospitalization in COPD

    by Terezia Pincikova, Tiphaine Parrot, Lena Hjelte, Marieann Högman, Karin Lisspers, Björn Ställberg, Christer Janson, Andrei Malinovschi, Johan K. Sandberg

    Background: Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation associated with chronic inflammation in the airways. Mucosal-associated invariant T (MAIT) cells are unconventional, innate-like T cells highly abundant in mucosal tissues including the lung. We hypothesized that the characteristics of MAIT cells in circulation may be prospectively associated with COPD morbidity. Methods: COPD subjects (n = 61) from the Tools for Identifying Exacerbations (TIE) study were recruited when in stable condition. At study entry, forced expiratory volume in 1 s (FEV1) was measured and peripheral blood mononuclear cells were cryopreserved for later analysis by flow cytometry. Patients were followed for 3 years to record clinically meaningful outcomes. Results: Patients who required hospitalization at one or more occasions during the 3-year follow-up (n = 21) had lower MAIT cell counts in peripheral blood at study inclusion, compared with patients who did not get hospitalized (p = 0.036). In contrast, hospitalized and never hospitalized patients did not differ in CD8 or CD4 T cell counts (p = 0.482 and p = 0.221, respectively). Moreover, MAIT cells in hospitalized subjects showed a more activated phenotype with higher CD38 expression (p = 0.014), and there was a trend towards higher LAG-3 expression (p = 0.052). Conventional CD4 and CD8 T cells were similar between the groups. Next we performed multi-variable logistic regression analysis with hospitalizations as dependent variable, and FEV1, GOLD 2017 group, and quantity or activation of MAIT and conventional T cells as independent variables. MAIT cell count, CD38 expression on MAIT cells, and LAG-3 expression on both MAIT and CD8 T cells were all independently associated with the risk of hospitalization. Conclusions: These findings suggest that MAIT cells might reflect a novel, FEV1-independent immunological dimension in the complexity of COPD. The potential implication of MAIT cells in COPD pathogenesis and MAIT cells’ prognostic potential deserve further investigation.


  • Open Access

    Vitamin D treatment modulates immune activation in cystic fibrosis

    by T Pincikova, D Paquin-Proulx, J K Sandberg, M Flodström-Tullberg, L Hjelte

    Summary: Persistent inflammatory response in cystic fibrosis (CF) airways is believed to play a central role in the progression of lung damage. Anti-inflammatory treatment may slow lung disease progression, but adverse side effects have limited its use. Vitamin D has immunoregulatory properties. We randomized 16 CF patients to receive vitamin D2, vitamin D3 or to serve as controls, and investigated the effect of vitamin D supplementation on soluble immunological parameters, myeloid dendritic cells (mDCs) and T cell activation. Three months of vitamin D treatment were followed by two washout months. Vitamin D status at baseline was correlated negatively with haptoglobin, erythrocyte sedimentation rate and immunoglobulin A concentration. Total vitamin D dose per kg bodyweight correlated with the down-modulation of the co-stimulatory receptor CD86 on mDCs. Vitamin D treatment was associated with reduced CD279 (PD-1) expression on CD4+ and CD8+ T cells, as well as decreased frequency of CD8+ T cells co-expressing the activation markers CD38 and human leucocyte antigen D-related (HLA-DR) in a dose-dependent manner. There was a trend towards decreased mucosal-associated invariant T cells (MAIT) cell frequency in patients receiving vitamin D and free serum 25-hydroxyvitamin D (free-s25OHD) correlated positively with CD38 expression by these cells. At the end of intervention, the change in free-s25OHD was correlated negatively with the change in CD279 (PD-1) expression on MAIT cells. Collectively, these data indicate that vitamin D has robust pleiotropic immunomodulatory effects in CF. Larger studies are needed to explore the immunomodulatory treatment potential of vitamin D in CF in more detail.


  • Open Access

    Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial

    by T Pincikova, D Paquin-Proulx, J K Sandberg, M Flodström-Tullberg, L Hjelte

    Background/Objectives: Vitamin D insufficiency in cystic fibrosis is common. Vitamin D3 is currently preferred over D2. We aimed to study the efficacy of vitamin D2 and D3 at increasing serum 25-hydroxyvitamin D (s25OHD) concentrations and their effect on respiratory health in cystic fibrosis. Subjects/Methods: Sixteen CF patients were randomized to receive vitamin D2 or D3 or to serve as controls. The starting dose of 5000 IU (PPP=0.006, r=0.90), and with changes in FEV1 (P=0.042, r=0.62) and FVC (P=0.036, r=0.63) at one month of washout. Conclusions: Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF.


  • Cystic fibrosis bronchial epithelial cells have impaired ability to activate vitamin D

    by Terezia Pincikova, Emma Svedin, Erna Domsgen, Malin Flodström‐Tullberg, Lena Hjelte


  • Vitamin D and cystic fibrosis

    by T. Pincikova, M. Flodström-Tullberg, Close

    Cystic fibrosis (CF) patients suffer from malnutrition and lung infections, both acute and chronic. The majority are also vitamin D insufficient despite vitamin D supplementation. With better medical care the life expectancy for CF patients has increased and so has the prevalence of longterm complications, such as bone disease and CF-related diabetes. Vitamin D insufficiency is associated with bone disease in CF, but evidence that vitamin D supplementation improves bone mineral density in CF patients is missing. The pathophysiology of vitamin D insufficiency in CF is multifactorial. Serum 25-hydroxyvitamin D (s25(OH)D) levels in CF patients fluctuate throughout the year, depending on the amount of UV exposure, with lowest values at the end of the winter. The current European and US guidelines for vitamin D supplementation for CF patients prefer colecalciferol over ergocalciferol, consider age of the patients, endorse individualisation of the supplementation regimen and are mostly consensus based due to lack of CF-specific evidence. In all age groups, s25(OH)D >50 nmol/l (Europe) or s25(OH)D >75 nmol/l (US) should be achieved and maintained. The current literature is missing CF-specific hard evidence on many issues, such as the optimal s25(OH)D level, the relative benefit of colecalciferol vs. ergocalciferol and daily vs. weekly supplementation regimen. The use of UV lamps is a promising alternative, but has so far been ineffective in raising s25(OH)D level in CF patients due to poor adherence with the treatment. In vitro experiments and human descriptive studies indicate that vitamin D might have beneficial immunomodulatory and glucose-lowering effects in CF patients, but a careful approach is to be recommended given the absence of well-designed intervention trials proving causality, safety and clinical relevance of the amplitude of the potential effects. There are a few registered trials currently running or planned to start soon, which address some of these questions.